| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition; Notice of Delisting or Failure to Satisfy a Listing Rule
Purchase, NY – November 5, 2026 – Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders (the “Company” or “Cognition”), today reported financial results... |
| 22 Oct 2026 |
8-K: Other Events
Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
Purchase, NY – August 6, 2026 – Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders (the “Company” or “Cognition”), today reported financial results f... |
| 24 Jun 2026 |
8-K: Other Events
Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes |
| 18 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 17, 2026, Cognition Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). The Annual Meeting was conducted virtually, and the following is a brief description of the final voting resul... |
| 04 Jun 2026 |
8-K: Regulation FD Disclosure
https://cogrx.com COGNITION THERAPEUTICS · NASDAQ: CGTX An Investigational Oral Therapy Advancing Toward Registrational Development June 2026 · Jefferies Global Healthcare Conference Zervimesine in DLB Psychosis |
| 21 May 2026 |
8-K: Other Events
- Positive Discussion on Path Forward for Registrational Program - |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
Meeting with FDA Division of Psychiatry scheduled for May 2026 expected to inform registrational plans for zervimesine in DLB psychosis |
| 26 Mar 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
March 2026 Zervimesine: a Once-daily Oral Therapeutic Advancing Toward Phase 3 |
| 02 Mar 2026 |
8-K: Other Events
- Regulatory strategy expedites development of potential first treatment to address DLB psychosis - |
| 27 Jan 2026 |
8-K: Other Events
PURCHASE, NY – January 27, 2026 – Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, conducted a Type C meeting with the U.S. Food an... |
| 18 Dec 2025 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement
On December 18, 2025, Cognition Therapeutics, Inc. (the “Company”) entered into an Open Market Sale AgreementSM (the “Sales Agreement”) with Jefferies LLC (“Jefferies”), pursuant to which the Company may sell, from time to time, at its o... |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition
Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs |
| 15 Sep 2025 |
8-K: Other Events
September 2025 Zervimesine: a Once-daily Oral Therapeutic Advancing Towards Phase 3 |
| 28 Aug 2025 |
8-K: Entry into a Material Definitive Agreement
This Securities Purchase Agreement (this “Agreement”) is dated as of August 27, 2025, between Cognition Therapeutics, Inc., a company incorporated under the laws of Delaware (the “Company”), and each purchaser identified on the signature... |
| 26 Aug 2025 |
8-K: Other Events
As previously disclosed, on September 12, 2024, Cognition Therapeutics, Inc. (the “Company”) received a deficiency letter from The Nasdaq Stock Market LLC (“Nasdaq”) stating that the bid price of its common stock had closed below the $1.... |
| 07 Aug 2025 |
8-K: Results of Operations and Financial Condition
Cognition Therapeutics Reports Financial Results for the Second Quarter 2025 and Highlights Progress Across Clinical Programs |
| 20 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 18, 2025, Cognition Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). The Annual Meeting was conducted virtually, and the following is a brief description of the final voting resul... |
| 03 Jun 2025 |
8-K: Other Events
Philanthropic Donor Funds Cognition Therapeutics’ Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies |
| 02 Jun 2025 |
8-K: Other Events
Targeting Pathogenic Oligomers: June 2025 A Disruptive Approach to the Treatment of Neurodegenerative Diseases |
Loading...